Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

47.66 -1.34 (-2.74%)

Streaming Delayed Price Updated: 3:16 PM EST, Nov 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

34 35 Next >

Wednesday Market Coverage ↗

October 20, 2021

Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal.

Via Talk Markets

Roche Expects Higher FY21 Sales As Delta Variant Boosts Demand For Diagnostics ↗

October 20, 2021

Roche Holding AG (OTC: RHHBY) raised its 2021 sales forecast after posting an 8% rise in nine-month revenues, driven by demand for COVID-19 tests and the strong...

Via Benzinga

AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial ↗

October 20, 2021

AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ...

Via Benzinga

The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review ↗

October 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19...

Via Benzinga

Bitcoin Futures Arrive ↗

October 19, 2021

Today you can finally hold Bitcoins via an exchange-traded fund.

Via Talk Markets

Why Atea Pharmaceuticals Is Imploding Today ↗

October 19, 2021

The company's oral COVID-19 treatment looks like a dud in the mild-to-moderate COVID-19 setting.

Via The Motley Fool

Atea Pharma Stock Crashes After Merck-Rivaling Covid Pill Lags In Midstage Test ↗

October 19, 2021

Atea Pharmaceuticals said its Covid pill didn't lower viral loads in all patients.

Via Investor's Business Daily

David v Goliath in The Race to Develop an Oral Therapy for COVID-19 ↗

October 19, 2021

Photo by Towfiqu barbhuiya on Unsplash Broad agreement in the world of science can be a rarity. However, one thing that public health leaders active in the fight against COVID-19...

Via Benzinga

The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio ↗

October 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In...

Via Benzinga

Why Are Atea Pharmaceuticals Shares Plunging Today? ↗

October 19, 2021

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate...

Via Benzinga

Chinese Growth Level ↗

October 18, 2021

The hot news today was a much weaker Chinese growth level this year, of 4.9% because of supply chain issues.

Via Talk Markets

Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage ↗

October 18, 2021

Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral...

Via Talk Markets

Ionis Stock Collapses On Another 'Misstep' As Biogen-Partnered ALS Drug Flops ↗

October 18, 2021

Biogen and Ionis' approach to Lou Gehrig's disease missed its key goal.

Via Investor's Business Daily

Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting ↗

October 18, 2021

The FDA has greenlit Roche Holdings AG's (OTC: RHHBY) Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with...

Via Benzinga

The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs ↗

October 18, 2021

Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....

Via Benzinga

Crispr: A Fallen Angel In Gene Editing ↗

October 16, 2021

As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it...

Via Talk Markets

Europe's Unicorns ↗

October 15, 2021

After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit.

Via Talk Markets

FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer

October 15, 2021

From Genentech

Via Business Wire

The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies ↗

October 15, 2021

Companies working on sorely needed Covid treatments are innovating to keep up.

Via Investor's Business Daily

NetworkNewsAudio – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Harnessing Power of Real-World Data

October 14, 2021

Via Investor Brand Network

This Company Revolutionizes What Matters for Hospitals, Big Pharma and Health Insurers ↗

October 14, 2021

You can perch on a 1-legged stool and balance precariously on 2, but if you want to settle in with comfort and safety, you need 3 sturdy legs. With its secure, cloud-based...

Via Benzinga

The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts ↗

October 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc...

Via Benzinga

New 4-Year Data Show Genentech’s Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder

October 14, 2021

From Genentech

Via Business Wire

New Data up to 8-Years for Genentech’s Ocrevus (ocrelizumab) Show Early and Ongoing Treatment Significantly Reduced Risk of Requiring a Walking Aid in Relapsing Multiple Sclerosis and Disability Progression in Primary Progressive Multiple Sclerosis

October 13, 2021

From Genentech

Via Business Wire

Real-World Data, Point-of-Care Testing Reshaping Healthcare, Detecting Diseases Sooner

October 12, 2021

Via Investor Brand Network

Biotech Stocks Are Lagging, Is It Time to Rebalance Your Healthcare Portfolio? ↗

October 11, 2021

You may have seen that biotech stocks have been in a funk. The IBB has broken through the SMA-200 support line near $160 and it holds a perilous perch at $155, up only about 2.5% year-to-date. The IBB...

Via Talk Markets

Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements ↗

October 11, 2021

Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK...

Via Benzinga

Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease

October 08, 2021

From Genentech

Via Business Wire

Roche's Alzheimer's Candidate Secures FDA Breakthrough Designation ↗

October 08, 2021

Roche Holdings AG's (OTC: RHHBY) gantenerumab antibody received breakthrough therapy designation from the FDA for Alzheimer's disease. Gantenerumab is...

Via Benzinga

Ad hoc announcement pursuant to Art. 53 LR: Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease

October 08, 2021

From Genentech

Via Business Wire

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Oil & Gas Journal starts where other industry publications stop. It delivers more than information; it delivers context, adding details the others leave out and combining them with analysis, commentary, industry trends, and statistics.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/ogjonline

https://www.linkedin.com/company/oil-&-gas-journal

http://twitter.com/ogjonline

Affiliated Brands

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions